Aktienanalyse zu Novavax Inc (NVAX)NVAXNovavax Inc

Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Novavax Inc is currently not a strong buy due to its recent price decline and mixed financial performance. The current price is $11.26, and the stock has experienced a 5-day change of -11.69%. Additionally, the RSI is at 39.319, indicating that the stock is nearing oversold territory but has not yet reversed its downward trend. The forward P/E ratio is 2.58, suggesting potential undervaluation, but the analyst price targets range from $8 to $9, indicating limited upside from current levels. The main risk is the recent negative sentiment, as the stock has dropped 10% following news of a broader market pullback in biotech stocks, which could further impact investor confidence.

7 analysts cover NVAX: 2 rate it Buy, 5 Hold and 0 Sell. The average price target is 10.50.